P16 modulates VEGF expression via its interaction with HIF-1α in breast cancer cells

Cancer Investigation

Volumn 28, Issue 6, 2010, Pages 588-597

  Zhang, Jun ^a   Lu, Andrew ^a,b   Li, Liyuan ^a   Yue, Junming ^a   Lu, Yi ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b PRINCETON UNIVERSITY   (United States)

Author keywords

Breast cancer; HIF 1a; P16; VEGF

Indexed keywords

ADENOVIRUS VECTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROTEIN P16; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER INHIBITION; CELL STRAIN HEK293; CELLULAR DISTRIBUTION; COMPLEX FORMATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; TRANSACTIVATION; TUMOR VASCULARIZATION; WESTERN BLOTTING;

ADENOVIRIDAE; ANIMALS; BINDING SITES; BREAST NEOPLASMS; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC VECTORS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; PROMOTER REGIONS, GENETIC; TRANSCRIPTIONAL ACTIVATION; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77953196949     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357900903286941     Document Type: Article

References (46)

1. Hanahan, D.; Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86, 353-364.
2. Grunstein, J.; Roberts, W.G.; Mathieu-Costello, O.; Hanahan, D.; Johnson, R.S. Tumor-derived expression of vascular endothelial growth factor is a critical factor in tumor expansion and vascular function. Cancer Res 1999, 59, 1592-1598.
3. Detmar, M.; Velasco, P.; Richard, L.; Claffey, K.P.; Streit, M.; Riccardi, L.; Skobe, M.; Brown, L.F. Expression of vascular endothelial growth factor induces an invasive phenotype in human squamous cell carcinomas. Am J Pathol 2000, 156, 159-167.
4. Risau, W. What, if anything, is an angiogenic factor? Cancer Metastasis Rev 1996, 15, 149-151.
5. Neufeld. G.; Cohen, T.; Gengrinovitch, S.; Poltorak, Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999, 13, 9-22.
6. Senger, D.R.; Galli, S.J.; Dvorak, A.M.; Perruzzi, C.A.; Harvey, V.S.; Dvorak, H.F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983, 219, 983-985.
7. Ferrara, N.; Henzel, W.J. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 1989, 16, 851-858.
8. Gasparini, G.; Toi, M.; Gion, M.; Verderio, P.; Dittadi, R.; Hanatani, M.; Matsubara, I.; Vinante, O.; Bonoldi, E.; Boracchi, P.; Gatti, C.; Suzuki, H.; Tominaga, T. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst 1997, 89, 139-144.
9. Yoshiji, H.; Gomez, D.E.; Shibuya, M.; Thorgeirsson, U.P. Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer. Cancer Res 1996, 56, 2013-2016.
10. Liotta, L.A.; Kleinerman, J.; Saidel, G.M. Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation. Cancer Res 1974, 4, 997-1004.
11. O'Reilly, M.S.; Holmgren, L.; Chen, C.; Folkman. J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nature Med 1996, 2, 689-692.
12. Michel, G.; Minet, E.; Mottet, D.; Remacle, J.; Michiels, C. Sitedirected mutagenesis studies of the hypoxia-inducible factor-1alpha DNA-binding domain. Biochim Biophys Acta 2002, 1578, 73-83.
13. Forsythe, J.A.; Jiang, B.H.; Iyer, N.V.; Agani, F.; Leung, S.W.; Koos, R.D.; Semenza, G.L. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996, 16, 4604-4613.
14. Roth, U.; Curth, K.; Unterman, T.G.; Kietzmann, T. The transcription factors HIF-1 and HNF-4 and the coactivator p300 are involved in insulin-regulated glucokinase gene expression via the phosphatidylinositol 3-kinase/protein kinase B pathway. J Biol Chem 2004, 279, 2623-2631.
15. Harada, H.; Nakagawa, K.; Iwata, S.; et al. Restoration of wild type p16 downregulates vascular endothelial growth factor expression and inhibits angiogenesis in human gliomas. Cancer Res 1999, 59, 3783-3789.
16. Semenza, G.L. Hydroxylation of HIF-1: oxygen sensing at the molecular level. Physiology (Bethesda) 2004, 19, 176-182.
17. Fatyol, K.; Szalay, A.A. The p14ARF tumor suppressor protein facilitates nucleolar sequestration of hypoxia-inducible factor-1alpha (HIF-1alpha) and inhibits HIF-1-mediated transcription. J Biol Chem 2001, 276, 28421-28429.
18. Liao, D.; Corle, C.; Seagroves, T.N.; Johnson, R.S. Hypoxiainducible factor-1 alpha is a key regulator of metastasis in a transgenic model of cancer initiation and progression. Cancer Res 2007, 67, 563-572.
19. Hiraga, T.; Kizaka-Kondoh, S.; Hirota, K.; Hiraoka, M.; Yoneda, T. Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer. Cancer Res 2007, 67, 4157-4163.
20. Dvorak, H.F.; Nagy; J.A.; Feng, D.; et al. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr Top Microbiol Immunol 1999, 237, 97-132. (Pubitemid 28554861)
21. Maynard, M.A.; Ohh, M. The role of hypoxia-inducible factors in cancer. Cell Mol Life Sci 2007, 64, 2170-2180.
22. INK4A as a human tumor suppressor. Biochem Biophys Acta 1996, 1242, 165-169.
23. Cairns, P.; Polascik, T.J.; Eby, Y.; Sidransky, D. High frequency of homozygous deletion at p16/CDKN2 in primary human tumors. Nature Genet 1995, 11, 210-212.
24. Quan, Z.W.; Wu, K.; Wang, J.; Shi, W.; Zhang, Z.; Merrell, R.C. Association of p53, p16, and vascular endothelial growth factor protein expressions with the prognosis and metastasis of gall bladder cancer. J Am Coll Surg 2001, 193, 380-383.
25. Steiner, M.S.; Zhang, Y.; Farooq, F.; Lerner, J.; Wang, Y.; Lu, Y. Adenoviral vector containing wild type p16 suppresses prostate cancer growth and prolongs survival by inducing cell senescence. Cancer Gene Ther 2000, 7, 360-372.
26. Lu, Y.; Carraher, J.; Zhang, Y.; Armstrong, J.; Lerner, J.; Roger, W.; Steiner, M.S. Delivery of adenoviral vectors to the prostate for gene therapy. Cancer Gene Ther 1999, 6, 64-72.
27. Steiner, M.S.; Zhang, Y.; Lu, Y. A fast way to generate recombinant adenovirus: a high-frequency-recombination system. J Industr Microbiol Biotechnol 2000, 24, 198-202.
28. Graham, F.L.; Prevec, L. Gene transfer and expression protocols. In Methods in Molecular Biology. E.J. Murray (ed.). Totowa, NJ: Humana Press, 1991, 109-128.
29. Lu, Y.; Whitaker, L.L.; Li, X.; Lotan, D.; Lotan, R. Co-expression of galectin-1 and its complementary glycoconjugates laminin and lysosome-associated membrane proteins in murine PCC4.aza1R embryonal carcinoma cells induced to differentiation by butyrate. Mol Cell Differ 1995, 3, 175-191.
30. Liu, M.; Wikonkal, N.M.; Brash, D.E. Induction of cyclin-dependent kinase inhibitors and G(1) prolongation by the chemopreventive agent N-acetylcysteine. Carcinogenesis 1999, 20, 1869-1872.
31. Abe, T.; Okamura, K.; Ono, M.; Kohno, K.; Mori, T.; Hori, S.; Kuwano, M. Induction of vascular endothelial tubular morphogenesis by human glioma cells: a model system for tumor angiogenesis. J Clin Invest 1993, 92, 54-61.
32. Sullivan, R.; Graham, C.H. Hypoxia-driven selection of the metastatic phenotype. Cancer Metastasis Rev 2007, 26, 319-331.
33. Chan, D.A.; Giaccia, A.J. Hypoxia, gene expression, and metastasis. Cancer Metastasis Rev 2007, 26, 333-339.
34. Subarsky, P.; Hill, R.P. The hypoxic tumour microenvironment and metastatic progression. Clin Exp Metastasis 2003, 20, 237-250.
35. Cairns, R.A.; Hill, R.P. Acute hypoxia enhances spontaneous lymph node metastasis in an orthotopic murine model of human cervical carcinoma. Cancer Res 2004, 64, 2054-2061.
36. Stackpole, C.W.; Groszek, L.; Kalbag, S.S. Benign-tomalignant B16 melanoma progression induced in two stages in vitro by exposure to hypoxia. J Natl Cancer Inst 1994, 86, 361-367.
37. Semenza, G.L. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003, 3, 721-32.
38. Hockel, M.; Vaupel, P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001, 93, 266-276.
39. Obermair, A.; Kucera, E.; Mayerhofer, K.; et al. Vascular endothelial growth factor (VEGF) in human breast cancer: correlation with disease-free survival. Int J Cancer 1997, 74, 455-458.
40. Gasparini, G.; Toi, M.; Gion, M.; et al. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst 1997, 89, 139-144.
41. Heffelfinger, S.C.; Miller, M.A.; Yassin, R.; Gear, R. Angiogenic growth factors in preinvasive breast disease. Clin Cancer Res 1999, 5, 2867-2876.
42. Bouvet, M.; Ellis, L.M.; Nishizaki, M.; et al. Adenovirus-mediated wild-type p53 gene transfer downregulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer. Cancer Res 1998, 58, 2288-2292.
43. Claudio, P.P.; Stiegler, P.; Howard, C.M.; et al. RB2/p130 geneenhanced expression down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in vivo. Cancer Res 2001, 61, 462-468.
44. Yeo, E.J.; Ahn, M.; Jung, K.; et al. YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J Natl Cancer Inst 2003, 95, 516-525.
45. Mabjeesh, N.J.; Escuin, D.; LaVallee, T.M.; et al. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 2003, 3, 363-375.
46. Steeg, P.S.; Hartsough, M.T.; Clare, S.E. Nm23, breast differentiation, and cancer metastasis. In Breast Cancer, A.M. Bowcock (ed.). Totowa, NJ: Humana Press, 1998, 267-283.